Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study.

Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study.

Item

http://www.wikidata.org/entity/Q34196792

Q34196792

about

Optimal timing for antiretroviral therapy initiation in patients with HIV infection and concurrent cryptococcal meningitis Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings Integrated therapy for HIV and cryptococcosis Vaccine-mediated immune responses to experimental pulmonary Cryptococcus gattii infection in mice Treatment of cryptococcosis in the setting of HIV coinfection.Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.Cryptococcal meningitis: epidemiology and therapeutic options.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer HIV: primary and secondary prophylaxis for opportunistic infections.Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the An update on Cryptococcus among HIV-infected patients.Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice.Prevention of HIV-associated opportunistic infections and diseases in the age of highly active antiretroviral therapy.Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models.Epidemiology and management of cryptococcal meningitis: developments and challenges.Current options in antifungal pharmacotherapy.New Insights into HIV/AIDS-Associated Cryptococcosis.Antifungal Activity of Plasmacytoid Dendritic Cells against Cryptococcus neoformans In Vitro Requires Expression of Dectin-3 (CLEC4D) and Reactive Oxygen Species.A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins.Treatment of cryptococcal meningitis in resource limited settings Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responses New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis.Cryptococcus antigens and immune responses: implications for a vaccine.Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study.Nanoparticle-Based Mycosis Vaccine.Methodology for Anti-Cryptococcal Vaccine Development.Relapsed Pulmonary Cryptococcosis during Tumor Necrosis Factor α Inhibitor Treatment Recurrence of cryptococcal meningitis in HIV-infected patients following immune reconstitution.Induction of Broad-Spectrum Protective Immunity against Disparate Cryptococcus Serotypes.Cryptococcosis.The war on cryptococcosis: A Review of the antifungal arsenal.An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.

P2860

Q24200929-4BF08AC0-1EB7-4F1E-B310-1FC7A644D1B3 Q24241096-F9976C76-4A8D-4409-B28E-778538A9C6C0 Q28077707-2FD5E90E-144A-494E-B166-C8EF459F3134 Q28541882-9AFD594E-9CD4-426B-BCBD-4A4556135168 Q30366117-94A1E703-C70B-47D3-BB14-518E64813499 Q33277939-B3E56A90-CB60-4B46-AA52-96EC0EB4CA90 Q33633343-5F9AE79A-248B-4B34-865D-3B3947683021 Q33650105-62E3E73E-682A-48E8-841E-12493F697214 Q33850498-EEEA1280-0583-42BD-8594-5B2947960D69 Q34020746-EEDFBA28-951C-4459-AC5F-AB6409E221EC Q34212799-6810A103-693B-49F4-AB64-0BF1BD9AF788 Q34625655-BEED0088-1CD8-4EA4-B5DE-27030B12C47D Q35066122-6746B0BE-8142-4322-9D2D-AAB4EEF657E9 Q35917465-B760408F-D3D3-487C-8D8B-F15A6B6AF153 Q36192774-90244302-8004-4D6D-BED0-6B769FD801BF Q37098995-EA824611-83D7-4529-8250-91E37C3A7F2A Q37151326-034F258A-439C-46DB-8110-38187857A10E Q37156556-BF67F36F-B959-4A45-8A34-D4EF80AE0148 Q37199814-ABA23D48-C119-4919-9BB5-062275A15955 Q37367575-59147244-7E24-4FEC-9335-6E7D60377503 Q37545277-168AC112-B923-461B-A575-D51B5C8A8CB1 Q37562226-F89F6F19-3B79-472F-9F86-F984A95E35A4 Q38024052-FDF3D9F8-C214-407B-9742-1CD44A3F9907 Q38155197-D38615A0-7DE4-4038-871A-146B7BAC79F6 Q39284131-80BFBFF8-524B-4AC2-B905-056E803A5939 Q40183778-5B145EFD-42B1-4596-90C3-BDDA1A8D7367 Q40183788-610805ED-53A5-408F-8254-8076E8E9337B Q40511245-EE1F7A1F-5757-400F-9926-C10AADD8360C Q44454415-18CC7F10-BF8E-44FA-99C7-3095220ADB7A Q47118458-BD8BA985-4F4B-4FA7-92E9-90D68A5E5E96 Q51818572-387D08FF-C0D8-4CCC-8B8B-38D25084245E Q54260674-244FE4CE-AB89-4B7D-9543-FC02D6C35225 Q54394711-43A2406E-4D87-4D3D-9814-93A5AD3A37C9

P2860

Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study.

Item

http://www.wikidata.org/entity/Q34196792

description

2003 nî lūn-bûn

@nan

2003 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu